COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic announces publication of phase 1/1b clinical trial data of IMU-856 in The Lancet Gastroenterology & Hepatology. Positive results in celiac disease patients. Potential new approach for gastrointestinal diseases -
-
-
COMMUNIQUÉ DE PRESSE
Inside Information / Other news releases
Mauna Kea Technologies provides an update on recent developments including the launch of its CellTolerance program for food intolerances and strategic initiatives to strengthen its financial structure and commercialize innovative solutions -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: APONTIS PHARMA AG (von Montega AG): Verkaufen (zuvor: Halten)
Montega AG stuft APONTIS PHARMA AG von Verkaufen auf Halten herab und senkt das Kursziel auf 10,00 EUR. Umsatzprognose gesenkt auf 48,7 Mio. EUR aufgrund verzögerter Wirkung der neuen Vertriebsstrategie -
-
